Incyte (INCY) Other Non Operating Income (2017 - 2026)
Incyte's (INCY) quarterly Other Non Operating Income came in at $6.3 million in Q2 2026, down 14.12% YoY from $7.3 million in Q2 2025, and up 126.21% on a QoQ basis from $2.8 million in Q1 2026.
Analysis
Incyte (INCY) Other Non Operating Income (2017 - 2026) Analysis & Trends
Incyte (INCY) has 10 years of Other Non Operating Income data on file, last reported at $6.3 million in Q2 2026.
- Quarterly Other Non Operating Income fell 14.12% year-over-year to $6.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $18.8 million (down 14.53% YoY) and the FY2025 annual result came in at $25.1 million, up 96.03% from the prior year.
- Other Non Operating Income improved to $6.3 million in Q2 2026, from $2.8 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $46.4 million in Q3 2023 to a low of -$108.0 million in Q4 2023.
- A 5-year average of $3.4 million and a median of $5.3 million in 2024 frame the typical range for Other Non Operating Income.
- The widest YoY moves for Other Non Operating Income: up 8073.95% in 2023, down 681.66% in 2023.
- Tracing INCY's Other Non Operating Income over 5 years: stood at -$13.8 million in 2022, then tumbled by 681.66% to -$108.0 million in 2023, then jumped by 101.49% to $1.6 million in 2024, then jumped by 251.15% to $5.7 million in 2025, then gained by 10.79% to $6.3 million in 2026.
- The last three Other Non Operating Income figures came in at $6.3 million (Q2 2026), $2.8 million (Q1 2026), and $5.7 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.21 Bn | 132.36 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.73 Bn | 58.55 Bn | 1.37 Bn |
| 4 | Moderna | 57.59 Bn | 52.46 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 40.13 Bn | 35.04 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.55 Bn | 32.24 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.60 Bn | 27.77 Bn | - |
| 9 | Insmed | 27.70 Bn | 26.54 Bn | 358.27 Mn |
| 10 | Incyte | 25.52 Bn | 20.98 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.28 Mn |
| Mar 31, 2026 | 2.77 Mn |
| Dec 31, 2025 | 5.66 Mn |
| Sep 30, 2025 | 4.04 Mn |
| Jun 30, 2025 | 7.31 Mn |
| Mar 31, 2025 | 8.10 Mn |
| Dec 31, 2024 | 1.61 Mn |
| Sep 30, 2024 | 4.93 Mn |
| Jun 30, 2024 | 8.29 Mn |
| Mar 31, 2024 | -2.03 Mn |
| Dec 31, 2023 | -107.98 Mn |
| Sep 30, 2023 | 46.37 Mn |
| Jun 30, 2023 | 42.67 Mn |
| Mar 31, 2023 | 32.87 Mn |
| Dec 31, 2022 | -13.81 Mn |
| Sep 30, 2022 | 11.51 Mn |
| Jun 30, 2022 | 522,000.00 |
| Mar 31, 2022 | 1.26 Mn |
| Dec 31, 2021 | 5.72 Mn |
| Sep 30, 2021 | 1.95 Mn |